ABSTRACT

Risk Categories in CLL Several risk categories can be distinguished in CLL patients based on response to treatment and cytogenetic and molecular changes. In the scheme proposed by Zenz et al., patients with CLL are divided into highest risk, high risk, and low risk [10]:

• Highest-risk CLL category includes patients with TP53 loss/mutations, lack of response to purine analogs, or very short response (<24 months) to prior treatment with udarabine, cyclophosphamide, and rituximab. ese patients are candidates for drugs with proven activity in TP53 deleted/mutant cells, investigational agents, and allogeneic stem cell transplantation.